Merck Sharp & Dohme Launches SAFLUTAN™ (tafluprost) in International Markets
WHITEHOUSE STATION, N.J., U.S.A.--(BUSINESS WIRE)--Merck Sharp & Dohme (MSD) has launched SAFLUTAN™ (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today. Tafluprost, the first preservative-free ophthalmic prostaglandin, is licensed in the launch markets for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle [...more]
